Dxcover

Dxcover has developed a proprietary liquid biopsy platform using multiomic spectral analysis powered by artificial intelligence. The company’s tests analyze panomic biomarkers from small volumes of blood or serum to detect early-stage cancers rapidly—often within one day—without the need for specialized sample preparation. Their lead program focuses on brain tumor detection where no other biomarker test exists. The technology has been validated across more than nine thousand patients and over two hundred fifty thousand spectra, showing robust diagnostic performance with tunable sensitivity/specificity. The company aims to enable earlier diagnosis of multiple solid tumors including brain, colorectal, lung, pancreatic, ovarian and kidney cancers.